eXoZymes, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EXOZ research report →
Price Chart
About the company
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing.
- CEO
- Michael Heltzen
- IPO
- 2024
- Employees
- 32
- HQ
- Monrovia, CA, US
Get TickerSpark's AI analysis on EXOZ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $65.34M
- P/E
- -5.87
- PEG
- 0.97
- P/S
- 0.00
- P/B
- 16.68
- EV/EBITDA
- -5.74
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -292.13%
- ROIC
- -155.79%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-9,716,471
- Net Income
- $-9,158,734-56.3%
- EPS
- $-1.09-51.4%
- OCF Growth
- +23.6%
- FCF Growth
- +25.1%
- 52W High
- $18.40
- 52W Low
- $4.35
- 50D MA
- $6.42
- 200D MA
- $9.76
- Beta
- 2.93
- RSI (14)
- 66
- Avg Volume
- 9.53K
No earnings-call transcripts are available for EXOZ yet.
- Free Float
- 26.7%
- Shares Outstanding
- 9.28M
- Float Shares
- 2.48M
of shares held by institutions
7 13F filers
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 31.52K | ▲ 5.54K |
Held by 17 ETFs
Biggest fund positions in EXOZ by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 8, 26 | Korman Tyler Paz | sell | 750 |
| Apr 9, 26 | Korman Tyler Paz | sell | 750 |
| Apr 1, 26 | Perriman Damien Alan | other | 146,437 |
| Apr 1, 26 | Perriman Damien Alan | other | 62,759 |
| Apr 1, 26 | Perriman Damien Alan | other | 0 |
| Apr 1, 26 | Perriman Damien Alan | other | 8,887 |
| Apr 1, 26 | Opgenorth Paul Hideo | other | 3,999 |
| Apr 1, 26 | Nawaz Fouad | other | 5,999 |
| Apr 1, 26 | Korman Tyler Paz | other | 5,332 |
| Jul 2, 25 | Heltzen Michael | buy | 1,040 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EXOZ coverage
Recent articles, reports, and earnings notes.
No research on EXOZ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EXOZ report →eXoZymes Q2 Earnings Call Highlights
marketbeat.com · Aug 20
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
accessnewswire.com · Aug 20
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
accessnewswire.com · Aug 18
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
accessnewswire.com · Aug 11
eXoZymes (NASDAQ:EXOZ) Shares Down 1.1% – What’s Next?
defenseworld.net · Aug 4
eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing
accessnewswire.com · Jul 23
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
accessnewswire.com · Jun 24
eXoZymes Inc. Announces Closing of $6 Million Public Offering
accessnewswire.com · Jun 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.